Adamalysines as Biomarkers and a Potential Target of Therapy in Colorectal Cancer Patients: Preliminary Results

Abstract EN

Colorectal cancer is one of the most common cancers in the world.

Due to its still undetermined pathogenesis, we are searching for signaling pathways that are important in the development of colorectal cancer.

In this article, we present results of study on the role of ADAM proteins in colorectal cancer.

The study included 85 adult colorectal cancer patients (48 men, 37 women) and 25 patients in the control group (after diagnostic colonoscopy—without cancer).

During hospitalization, a serum sample (3 cm3) was collected from the study and control group, anthropometric measurements were conducted and others clinical data were analyzed.

In the serum ADAM10, 12, 17, and 28, protein concentrations were determined and, in the next step, examined the relationship between ADAMs concentrations and selected clinical parameters in both groups.

The analysis showed that serum levels of ADAM10 and ADAM28 are significantly higher in patients with colorectal cancer and correlate with histopathological grading and with presence of distant metastases.

Moreover, noticed the trend to correlate concentrations of adamalysines with higher BMI score.

One of the functions of adamalysines is the activation of growth factors involved in cancer, including IGF and TNFα.

The increased activity of adamalysines in patients may play a role in the pathogenesis of colorectal cancer.

Our study highlights the prevalence of metabolic disorders in the group of patients with diagnosed CRC, and this cancer seems to be a further complication of obesity.